Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

Abstract Objective Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA). Data from these trials were used to identify basel...

Full description

Bibliographic Details
Main Authors: Josef S. Smolen, Young Mo Kang, Wan-Hee Yoo, Paul Emery, Michael E. Weinblatt, Edward C. Keystone, Mark C. Genovese, Gihyun Myung, Inyoung Baek, Jeehoon Ghil
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Arthritis Research & Therapy
Subjects:
Biosimilar
TNF inhibitors
Rheumatoid arthritis
Radiography
Online Access:http://link.springer.com/article/10.1186/s13075-020-02267-z

Internet

http://link.springer.com/article/10.1186/s13075-020-02267-z

Similar Items